Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Clinical trial NCT02906332 · TERMINATED
Trial details
- NCT number
- NCT02906332
- Sponsor
- Hackensack Meridian Health
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-12
- Primary completion
- 2022-05-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.